Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up

Sia V. Lindskrog[1,2], Karin Birkenkamp-Demtröder[1,2], Iver Nordentoft[1], George Laliotis[3], Philippe Lamy[1], Emil Christensen[1], Derrick Renner[3], Tine G. Andreasen[1,2], Naja Lange[1], Shruti Sharma[3], Adam C. ElNaggar[3], Minetta C. Liu[3], Himanshu Sethi[3], Alexey Aleshin[3], Mads Agerbæk[4], Jørgen B. Jensen[2,5], and Lars Dyrskjøt[1,2]

ABSTRACT

Purpose: To investigate whether circulating tumor DNA (ctDNA) assessment in patients with muscle-invasive bladder cancer predicts treatment response and provides early detection of metastatic disease.

Experimental Design: We present full follow-up results (median follow-up: 68 months) from a previously described cohort of 68 neoadjuvant chemotherapy (NAC)-treated patients who underwent longitudinal ctDNA testing (712 plasma samples). In addition, we performed ctDNA evaluation of 153 plasma samples collected before and after radical cystectomy (RC) in a separate cohort of 102 NAC-naïve patients (median follow-up: 72 months). Total RNA sequencing of tumors was performed to investigate biological characteristics of ctDNA shedding tumors.

Results: Assessment of ctDNA after RC identified metastatic relapse with a sensitivity of 94% and specificity of 98% using the

expanded follow-up data for the NAC-treated patients. ctDNA dynamics during NAC was independently associated with patient outcomes when adjusted for pathologic downstaging (HR = 4.7; $P = 0.029$). For the NAC-naïve patients, ctDNA was a prognostic predictor before (HR = 3.4; $P = 0.0005$) and after RC (HR = 17.8; $P = 0.0002$). No statistically significant difference in recurrence-free survival for patients without detectable ctDNA at diagnosis was observed between the cohorts. Baseline ctDNA positivity was associated with the Basal/Squamous (Ba/Sq) subtype and enrichment of epithelial-to-mesenchymal transition and cell cycle–associated gene sets.

Conclusions: ctDNA is prognostic in NAC-treated and NAC-naïve patients with more than 5 years follow-up and outperforms pathologic downstaging in predicting treatment efficacy. Patients without detectable ctDNA at diagnosis may benefit significantly less from NAC, but additional studies are needed.

Introduction

Bladder cancer is a common malignancy with more than 570,000 new cases each year worldwide (1), of which approximately 25% are diagnosed with muscle-invasive bladder cancer (MIBC). Despite curative intent treatment with neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC), approximately 50% of patients with localized MIBC develop metastatic disease (2) and only 40% to 45% have a pathologic response to NAC (3, 4). Early detection of metastatic relapse and effective monitoring of treatment response are therefore critical to improve patient outcomes.

Circulating tumor DNA (ctDNA) is a promising minimally invasive blood-based biomarker for early detection of metastatic relapse and

monitoring of treatment response in bladder cancer (5–7). Our group has previously demonstrated that ctDNA monitoring in patients with MIBC (median follow-up of 21 months after RC) can identify metastatic relapse with a median lead-time of 96 days over radiographic imaging (5). Several factors, including tumor stage and tumor size impact ctDNA detection (8–11). However, absence of ctDNA detection in advanced tumors of high volume has shown to be influenced by biological features such as age, obesity, and diabetes (12) and also tumor characteristics including histology and proliferation rates (13). Thus, establishment and validation of sensitive ctDNA detection methods and increased knowledge of tumor characteristics affecting ctDNA shedding in bladder cancer are needed to facilitate the implementation of ctDNA assessment in routine clinical practice. As late events may be more difficult to detect due to continued metastatic tumor evolution (14), evaluation of ctDNA-based stratification of patients having long-term clinical follow-up is of high importance.

Here, we present extended clinical follow-up results (median follow-up of 68 months after RC) from a previously described cohort of 68 NAC-treated patients (5). In addition, we performed ctDNA evaluation in a retrospectively collected cohort of 102 patients that did not receive NAC to compare recurrence rates between NAC-treated and NAC-naïve patients when stratified by ctDNA status. We investigated whether longitudinal ctDNA assessment in patients with MIBC predicts treatment response and early detection of metastatic relapse for both cohorts. Furthermore, we evaluated the underlying biology of metastatic relapse and ctDNA shedding using RNA sequencing (RNA-seq) data of the primary tumors at diagnosis.

[1]Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. [2]Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. [3]Natera, Austin, Texas. [4]Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. [5]Department of Urology, Aarhus University Hospital, Aarhus, Denmark.

Corresponding Author: Lars Dyrskjøt, Department of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus 8200, Denmark. E-mail: lars@clin.au.dk

Translational Relevance

Approximately 50% of patients diagnosed with localized muscle-invasive bladder cancer (MIBC) who are treated with neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) develop metastatic disease within 2 years and only 40% to 45% have a pathologic response to NAC. Assessment of circulating tumor DNA (ctDNA) is a promising noninvasive blood-based biomarker, which might improve the clinical management of patients with MIBC. Here we evaluate the potential of ctDNA analysis in early risk stratification, prediction of treatment response, and early detection of metastatic relapse in a NAC-treated patient cohort with more than 5 years of follow-up after RC. Furthermore, a NAC-naïve patient cohort was included to evaluate the prognostic potential of ctDNA in this setting. Our results lay the groundwork for establishment of new randomized trials evaluating ctDNA-guided therapeutic and bladder preserving approaches.

Materials and Methods

Patients and clinical samples

The study was conducted in accordance with the Declaration of Helsinki and all patients provided written informed consent to participate in future research projects. The human investigations were initiated following approval from The National Committee on Health Research Ethics (#1302183 and #1706291). Details of the 68 NAC-treated patient cohort have previously been described (5). Pathologic downstaging after NAC was defined as ≤pTa, CIS, N0. Additional ctDNA analysis of 56 plasma samples collected after RC was performed.

For the NAC-naïve cohort, we retrospectively included 102 patients diagnosed with MIBC who underwent RC without prior treatment with NAC at Aarhus University Hospital in Denmark between 2001 and 2014. Patients were recruited over a period of 13 years (2001–2014) when NAC was not standard-of-care in Denmark. Hence, the cohort might include both cisplatin-eligible and ineligible patients. The NAC-naïve cohort was selected to represent an equal number of patients with and without metastatic disease within the cohort and was not matched to the NAC-treated cohort. None of the patients received adjuvant chemotherapy but were treated at the time of relapse detection. Plasma samples collected before RC (at diagnosis or at previous visits due to NMIBC) and after RC were included and analyzed for presence of ctDNA (collection of samples between 2001 and 2016).

Clinical end points were obtained from radiographic imaging results and pathology reports [recurrence-free survival (RFS)] and from the nationwide civil registry [overall survival (OS)]. RC was not completed for patients 4175 and 4250 and recurrence assessment was not available for patient 4519, and these patients were therefore excluded from analyses of recurrence status. For patients in the NAC-naïve cohort, RFS was censored after 4 years of FU. Assessment of 12-month recurrence status was based on imaging data up to 14 months after RC to allow for variability in scheduling of imaging. Follow-up information was collected and managed using REDCap hosted at Aarhus University (15, 16).

Whole-exome sequencing

Whole-exome sequencing (WES) was performed on tumor embedded in Tissue-Tek O.C.T. Compound or formalin-fixed, paraffin-embedded (FFPE) tumor tissue along with matched peripheral blood mononuclear cell blood samples (germline) from each patient. Details and metrics of the NAC-treated 68-patient cohort were previously described (5). For the NAC-naïve cohort, WES of tumor and matched germline DNA was performed at a mean target coverage of 405X (range, 238–689X) for tumor samples and 94X (range, 60–139X) for germline samples.

Personalized ctDNA assay using multiplex PCR-based NGS workflow

Personalized, tumor-informed ctDNA assays (Signatera) were designed as previously described (5) and used for ctDNA detection and quantification. Briefly, up to 16 high-ranked, patient-specific, somatic, single-nucleotide variants (SNV) derived from WES of tumor tissue were selected for multiplex PCR (mPCR) testing. mPCR primers targeting the selected SNVs were designed, synthesized, and used for longitudinal ctDNA assessment. Plasma samples with at least two variants detected were defined as ctDNA-positive. ctDNA concentration was reported as mean tumor molecules per mL of plasma.

Details and metrics of the NAC-treated 68-patient cohort were previously described (5). For the NAC-naïve cohort, a median of 3.6 mL of plasma (range, 1.3–7.9 mL) was used for cell-free DNA (cfDNA) extraction. A median of 6.5 ng cfDNA per mL plasma (range, 0.79–799.8 ng/mL) was extracted.

Baseline ctDNA status was defined as the ctDNA status pre-NAC for the NAC-treated cohort and the ctDNA status pre-RC for the NAC-naïve cohort. Accumulated ctDNA status after RC was defined as any ctDNA-positive plasma sample during the surveillance period after RC. In addition, an evaluation of the prognostic potential of ctDNA detection after RC was performed with a restricted follow-up time after the last ctDNA analysis. Here, recurrence was defined as detection of clinical recurrence from radiographic imaging results up to 2 years after the last plasma sample was analyzed. No recurrence was defined as absence of clinical recurrence during the surveillance period of up to 2 years after the last plasma sample was analyzed, including only patients with at least 2 years of follow-up after RC. For the NAC-treated cohort, the accumulated ctDNA status within 1 year after RC was included to illustrate a defined time period of evaluating patient prognosis after RC. The accumulated ctDNA status within 1 year after RC was based on plasma samples up to 14 months after RC to allow for variability in sample collection. Again, recurrence was defined as detection of clinical recurrence from radiographic imaging results up to 2 years after the last plasma sample was analyzed (the last plasma sample within the 1-year time period after RC). No recurrence was defined as absence of clinical recurrence during the surveillance period of up to 2 years after the last plasma sample was analyzed, including only patients with at least 2 years of follow-up after RC.

Genomic characterization of tumors

The WES data of tumors from both patient cohorts were subsequently and separately analyzed for tumor characterization purposes (unrelated to the Signatera WES and personalized SNV assay design workflow). Reads were mapped with bwa-mem using the GRCh38 genome assembly, and SNVs and indels were called using Mutect2 (v2.2) and annotated using SnpEff (v4.3t). Variants with more than 2 alternate allele reads in the germline, less than three alternate allele reads in the tumor, or a tumor VAF below 5% were filtered out. All variants passing the above filters were included in the analysis of mutational signatures using SomaticSignatures (v2.30) and MutationalPatterns (v3.4.1). Tumors with <50 SNVs were excluded (23/170

tumors). Trinucleotide patterns for COSMIC signatures (v3.2) were obtained and used for analysis of the contribution of the four main signatures previously observed in bladder cancer (SBS1, SBS2, SBS5, SBS13), rather than performing *de novo* extraction of signatures. To ensure that the contribution of the selected COSMIC SBS signatures was representative of the observed mutational spectrum, the resulting trinucleotide mutational profile for every sample was compared with the original profile and only samples with a cosine similarity above 0.9 were considered (107/147 tumors). For the analysis of the number of SNVs and indels according to baseline ctDNA status, only variants with a high or moderate impact (based on SnpEff annotation) were included. When assessing the mutation rates of single genes between ctDNA-positive and -negative patients, a curated list of 78 bladder cancer driver genes from IntOGen was used.

Total RNA-seq and bioinformatics analysis

Tumor RNA was extracted using RNeasy Mini Kit (catalog no. 74106, Qiagen) for samples in TissueTech ($n = 98$) and Allprep DNA/RNA FFPE (catalog no. 80234, Qiagen) for FFPE samples ($n = 64$). Library preparation was performed using KAPA HyperPrep kit (RiboErase HMR, Roche) followed by sequencing on an Illumina NovaSeq 6000 generating a median of 110.7 million reads per sample (range, 6.4–507.5 million reads). Salmon (17) was used to quantify the amount of each transcript using annotation from Gencode release 33 on genome assembly GRCh38 and transcript-level estimates were imported and summarized at gene-level using the R package tximport (v1.20). ComBat-seq was used to adjust for batch effects between fresh-frozen and FFPE samples using the R package sva (v3.42). Samples with less than five million mapped reads were excluded and genes not expressed in at least 25% of samples were removed, resulting in 131/162 tumors. Adjusted counts were normalized using edgeR (v3.34.1): effective library sizes were calculated using the trimmed mean of M values methods and counts were transformed to log$_2$-counts-per-million. All tumors were classified according to the six consensus classes of MIBC (18) using the R package consensusMIBC (v1.1). Gene set enrichment analysis was performed using the R package fgsea (v1.20). Log-fold changes of genes between groups were estimated using genewise negative binomial generalized linear models (edgeR v3.36) and the Hallmark gene sets were extracted from the Molecular Signatures Database using msigdbr (v7.5.1).

Statistical analysis

Survival curves were compared using the Kaplan–Meier method. HRs, associated 95% confidence intervals (CI), and P values were calculated using Cox regression analysis (R packages survminer v0.4.9 and survival v3.2.13). Kruskal–Wallis test, Wilcoxon rank sum test, Fisher exact test, and Pearson χ^2 test were used to determine statistically significant associations. ctDNA growth rates (slow rise vs. fast rise) were calculated using a log-linear regression fitted to each patient based on ctDNA level as a function of time before clinical recurrence detection. The ctDNA growth rates were estimated from the slope of the regression lines. Analysis was performed using the R statistical environment (v4.1.2).

Data availability

The raw sequencing data generated in this study are not publicly available as this compromises patient consent and ethics regulations in Denmark. Processed nonsensitive data are available upon reasonable request from the corresponding author.

Table 1. Demographics and clinical characteristics of patient cohorts.

	NAC-treated cohort ($N = 68$)[a]	NAC-naïve cohort ($N = 102$)[a]	P value[b]
Age, years, median (IQR)	67 (59–71)	69 (62–75)	0.010
Sex			0.53
Female	12 (18%)	22 (22%)	
Male	56 (82%)	80 (78%)	
T-stage, TURBT			<0.001
Ta	0 (0%)	1 (1%)	
T1	2 (2.9%)	22 (22%)	
T2	59 (87%)	75 (74%)	
T3	1 (1.5%)	0 (0%)	
T4	6 (8.8%)	3 (3%)	
N-stage, TURBT			
N0	58 (85%)		
N1	7 (10%)		
N2	3 (4.4%)		
T-stage, RC			<0.001
T0/CIS/Ta	44 (67%)	27 (26%)	
T1	3 (4.5%)	8 (7.8%)	
T2	6 (9.1%)	23 (23%)	
T3	9 (14%)	35 (34%)	
T4	4 (6.1%)	9 (8.8%)	
N-stage, RC			0.059
N0	59 (88%)	79 (80%)	
N1	2 (3%)	13 (13%)	
N2	3 (4.5%)	6 (6.1%)	
N3	3 (4.5%)	1 (1%)	
Pathologic downstaging after NAC	44 (66%)		
Complete response after NAC	42 (63%)		
Recurrence	18 (28%)	44 (44%)	0.035
12-month recurrence	10 (15%)	29 (30%)	0.034
RFS, months, median (IQR)	24 (23–25)	24 (5–32)	0.10
2-year survival	57 (86%)	73 (72%)	0.037
5-year survival	48 (73%)	58 (57%)	0.049
OS, months, median (IQR)	68 (54–82)	72 (17–92)	0.042

Abbreviations: CIS, carcinoma in situ; IQR, interquartile range.
[a]Median (IQR); n (%).
[b]Wilcoxon rank sum test; Person's χ^2 test; Fisher exact test; Cox regression analysis.

Results

Cohort characteristics

We updated ctDNA data and clinical follow-up for 68 patients with MIBC who received NAC prior to RC (5). All patients were monitored longitudinally with plasma ctDNA testing. Additional ctDNA analysis of 56 plasma samples collected after RC was performed for 17 patients, resulting in a total of 712 plasma samples collected between 2014 and 2019 (Supplementary Fig. S1). Patients had an updated median follow-up of 68 months after RC and an observed recurrence rate of 28% (18/65 patients).

In addition, a cohort of 102 patients with MIBC who did not receive NAC before RC were retrospectively selected from our biobank for ctDNA analysis. Plasma samples procured before RC (110 samples from 101 patients) and after RC (43 samples from 35 patients) between 2001 and 2016 were included (Supplementary Fig. S2). Patients had a median follow-up of 72 months after RC and an observed recurrence

A ctDNA before NAC

RFS vs Days after RC

HR = 15.6 (3.5–69)
P = 0.00029

Negative	36	36	36	12	7
Positive	24	18	13	4	3

B ctDNA before NAC

OS vs Days after RC

HR = 8.9 (2.9–27.3)
P = 0.00012

Negative	36	36	36	34	28
Positive	25	20	14	12	5

C ctDNA before NAC

P = 0.00003

Rec n = 10: 100% Positive
No rec n = 50: 72% Negative, 28% Positive

Negative / Positive

D ctDNA before RC

RFS vs Days after RC

HR = 15.2 (5–46.8)
P < 0.00001

Negative	55	54	51	17	11
Positive	9	4	2	0	0

E ctDNA before RC

OS vs Days after RC

HR = 9 (3.6–22.6)
P < 0.00001

Negative	55	54	52	47	34
Positive	10	6	2	2	2

F ctDNA before RC

P = 0.00001

Rec n = 10: 30% Negative, 70% Positive
No rec n = 54: 96% Negative, 3.7% Positive

Negative / Positive

G ctDNA after RC

RFS vs Days after RC

HR = 37.7 (8.5–167.1)
P < 0.00001

Negative	48	48	48	15	9
Positive	17	11	6	3	2

H ctDNA after RC

OS vs Days after RC

HR = 19.5 (6.9–54.6)
P < 0.00001

Negative	48	48	48	44	34
Positive	18	13	7	6	2

I ctDNA after RC

P < 0.00001

Rec n = 16: 6.2% Negative, 94% Positive
No rec n = 48: 98% Negative, 2.1% Positive

Negative / Positive

J ctDNA 1 year after RC

RFS vs Days after RC

HR = 20.3 (6.5–63.7)
P < 0.00001

Negative	50	50	50	16	9
Positive	15	9	4	2	2

K ctDNA 1 year after RC

OS vs Days after RC

HR = 15.8 (6.2–40.2)
P < 0.00001

Negative	50	50	50	46	34
Positive	16	11	5	4	2

L ctDNA 1 year after RC

P < 0.00001

Rec n = 15: 20% Negative, 80% Positive
No rec n = 49: 96% Negative, 4.1% Positive

Negative / Positive

rate of 44% (44/100 patients). Clinical characteristics differed between cohorts as patients in the NAC-treated, prospective cohort were collected consecutively while the patients in the NAC-naïve cohort were retrospectively selected to include a similar number of patients with and without metastatic disease within the cohort (**Table 1**).

NAC-treated patient cohort: ctDNA detection is prognostic of outcomes

In this study with the updated clinical follow-up for the NAC-treated patients, ctDNA status remained highly prognostic of patient outcomes: at diagnosis before NAC (RFS: HR, 15.6; 95% CI, 3.5–69; $P = 0.0003$; OS: HR, 8.9; 95% CI, 2.9–27.3; $P = 0.0001$), after NAC prior to RC (RFS: HR, 15.2; 95% CI, 5–46.8; $P < 0.0001$; OS: HR, 9; 95% CI, 3.6–22.6; $P < 0.0001$), after RC (accumulated ctDNA status; RFS: HR, 37.7; 95% CI, 8.5–167.1; $P < 0.0001$; OS: HR, 19.5; 95% CI, 6.9–54.6; $P < 0.0001$), and within 1 year after RC (accumulated ctDNA status; RFS: HR, 20.3; 95% CI, 6.5–63.7; $P < 0.0001$; OS: HR, 15.8; 95% CI, 6.2–40.2; $P < 0.0001$; **Fig. 1A–L**). Notably, all patients with disease recurrence within the first year after RC were ctDNA-positive at diagnosis before NAC (**Fig. 1C**). Five additional patients experienced metastatic relapse 20 to 61 months after RC with the extended follow-up. Of these, three patients (4422, 4479, and 4496) were ctDNA-positive before NAC and during surveillance within the first 2 years after RC. Thereby, using full follow-up during surveillance after RC, we observed an overall recurrence rate of 94% (16/17) for ctDNA-positive patients and 4.2% (2/48) for ctDNA-negative patients (accumulated ctDNA status; 89% sensitivity, 98% specificity). For the remaining two patients (3889 and 3997) being ctDNA-negative after RC but experiencing metastatic relapse, the last available plasma samples were collected 1,097 and 463 days before the clinical relapse, respectively. Restricting the analysis to include 2 years of follow-up after the last ctDNA analysis resulted in a recurrence rate of 94% (15/16) for ctDNA-positive patients and 2% (1/48) for ctDNA-negative patients (accumulated ctDNA status; 94% sensitivity, 98% specificity; **Fig. 1I**).

For patients with metastatic relapse and detectable ctDNA ($n = 16$), ctDNA analysis during surveillance after RC had a median lead-time of 123 days over radiographic imaging (range, −83 to 1,478 days; $P = 0.003$, full follow-up included; **Fig. 2A**). Importantly, ctDNA analysis had a median lead-time of 118 days over radiographic imaging ($P = 0.011$) when restricting the analysis to patients with simultaneous plasma samples and imaging (imaging performed ±1 month of the ctDNA analysis, $n = 13$). We found an increase in ctDNA levels before clinical relapse for the 10 patients with metastatic relapse and ≥2 consecutive ctDNA-positive plasma samples available before/after clinical relapse (**Fig. 2B**). Interestingly, patients with longer lead-times (>200 days) had a slower rise in ctDNA levels (mean slope

of 0.004) compared with patients with shorter lead-times (mean slope of 0.02; including patients with ≥2 consecutive ctDNA-positive plasma samples within 365 days before and 30 days after their clinical relapse; **Fig. 2C**).

ctDNA measurements for monitoring treatment response

As previously described, pathologic downstaging to a noninvasive stage (≤pTa, CIS, N0) after NAC was observed for 67% of patients (44/66; ref. 5). For patients without pathologic downstaging, only 43% (9/21) had metastatic relapse within the first year after RC, indicating that pathologic downstaging is suboptimal for evaluating treatment efficacy. Of the 36 patients who were ctDNA-negative at diagnosis of MIBC, 89% (32/36) achieved pathologic downstaging (**Fig. 2D**). Likewise, 80% (44/55) of patients who were ctDNA-negative after NAC prior to RC achieved pathologic downstaging, whereas none of the ctDNA-positive patients had pathologic downstaging (**Fig. 2E**). When evaluating ctDNA dynamics (measurements before and after NAC), 56% (9/16) of patients with ctDNA clearance achieved pathologic downstaging while none of the patients persistently positive achieved pathologic downstaging (**Fig. 2F**). For patients who were ctDNA-positive before treatment, clearance of ctDNA was significantly associated with disease relapse within 1 year after RC ($P = 0.002$; **Fig. 2G**) and full follow-up RFS (HR, 6.5; 95% CI, 2–21.4; $P = 0.002$; **Fig. 2H**). Pathologic downstaging was significantly associated with disease relapse within 1 year ($P = 0.03$; **Figure 2I**), but not RFS using the same patient subset (**Fig. 2J**). Of note, multivariable Cox regression analysis revealed both ctDNA positivity before RC (HR, 5.4; 95% CI, 1.5–19.1; $P = 0.009$) and absence of ctDNA clearance after NAC (HR, 4.7; 95% CI, 1.2–18.8; $P = 0.029$) were independently associated with worse RFS when adjusted for pathologic downstaging (Supplementary Table S1), indicating that ctDNA analysis might be an appropriate tool to evaluate treatment efficacy as well as to identify high risk patients before RC is performed.

NAC-naïve cohort: ctDNA detection is prognostic of outcomes

For the NAC-naïve patients, the presence of ctDNA was a strong prognostic predictor of patient outcomes: at diagnosis before RC (RFS: HR, 3.4; 95% CI, 1.7–6.8; $P = 0.0005$) and after RC (accumulated ctDNA status; RFS: HR, 17.8; 95% CI, 3.9–81.2; $P = 0.0002$; **Fig. 3A–F**). In this cohort, accumulated ctDNA status during disease surveillance after RC identified metastatic relapse with 82% sensitivity and 94% specificity (**Fig. 3F**; recurrence evaluation within 2 years after the last plasma sample was analyzed for ctDNA). In concordance with previously published results on patients not receiving NAC (19), surgical downstaging to a noninvasive stage (≤pTa, CIS, N0) and complete resection (pT0, N0) at RC by transurethral resection of the


Figure 1.
ctDNA detection for prognosis assessment in patients treated with NAC. **A,** Kaplan–Meier survival analysis of RFS and plasma ctDNA status before NAC. **B,** Kaplan–Meier survival analysis of OS and plasma ctDNA status before NAC. **C,** Association between plasma ctDNA status before NAC and recurrence status within 1 year after RC including only patients with at least 1 year of follow-up after RC. **D,** Kaplan–Meier survival analysis of RFS and plasma ctDNA status before RC. **E,** Kaplan–Meier survival analysis of OS and plasma ctDNA status before RC. **F,** Association between plasma ctDNA status before RC and recurrence status within 1 year after RC including only patients with at least 1 year of follow-up after RC. **G,** Kaplan–Meier survival analysis of RFS and accumulated plasma ctDNA status after RC. **H,** Kaplan–Meier survival analysis of OS and accumulated plasma ctDNA status after RC. **I,** Association between accumulated plasma ctDNA status after RC and recurrence. Recurrence was defined as detection of clinical recurrence from radiographic imaging results up to 2 years after the last plasma sample was analyzed. No recurrence was defined as absence of clinical recurrence during the surveillance period of up to 2 years after the last plasma sample was analyzed, including only patients with at least 2 years of follow-up after RC. **J,** Kaplan–Meier survival analysis of RFS and accumulated plasma ctDNA status within 1 year after RC. **K,** Kaplan–Meier survival analysis of OS and accumulated plasma ctDNA status within 1 year after RC. **L,** Association between accumulated plasma ctDNA status within 1 year after RC and recurrence. Recurrence was defined as detection of clinical recurrence from radiographic imaging results up to 2 years after the last plasma sample was analyzed (the last plasma sample within the 1-year time period after RC). No recurrence was defined as absence of clinical recurrence during the surveillance period of up to 2 years after the last plasma sample was analyzed, including only patients with at least 2 years of follow-up after RC. HRs, associated 95% CIs, and P values are displayed on each Kaplan–Meier plot (Cox regression analysis). Significant statistical difference between ctDNA status and recurrence was determined using Fisher exact test.

Figure 2.
ctDNA measurements for monitoring relapse and treatment response. **A,** Lead time in days between molecular recurrence (ctDNA positivity) and clinical recurrence (radiographic imaging positive). Statistical significance was calculated using paired Wilcoxon rank sum test. Longer lead-time was defined as >200 days between molecular and clinical recurrence. **B,** ctDNA levels at the time of clinical recurrence (radiographic imaging positive, time point zero) for patients having at least two plasma samples analyzed for ctDNA at the time of their clinical relapse. **C,** Linear regression lines of ctDNA levels at the time of clinical recurrence (radiographic imaging positive, time point zero) for patients having at least two plasma samples analyzed for ctDNA at the time of their clinical relapse. Longer lead-time was defined as > 200 days between molecular and clinical recurrence. **D,** Association between ctDNA status before NAC and pathologic downstaging. **E,** Association between ctDNA status before RC and pathologic downstaging. **F,** Association between ctDNA clearance after NAC and pathologic downstaging. **G,** Association between ctDNA clearance after NAC and recurrence status within 1 year after RC for patients being ctDNA-positive before NAC. **H,** Kaplan–Meier survival analysis of RFS and ctDNA clearance after NAC for patients being ctDNA-positive before NAC. **I,** Association between pathologic downstaging and recurrence status within 1 year after RC for patients being ctDNA-positive before NAC. **J,** Kaplan–Meier survival analysis of RFS and pathologic downstaging for patients being ctDNA-positive before NAC. HRs, associated 95% CIs, and P values are displayed on each Kaplan–Meier plot (Cox regression analysis). Significant statistical difference between categorical variables was determined using Fisher exact test.

Figure 3.
ctDNA detection for prognosis assessment in patients not treated with NAC. **A,** Kaplan–Meier survival analysis of RFS and plasma ctDNA status before RC. **B,** Kaplan–Meier survival analysis of OS and plasma ctDNA status before RC. **C,** Association between plasma ctDNA status before RC and recurrence status within 1 year after RC including only patients with at least 1 year of follow-up after RC. **D,** Kaplan–Meier survival analysis of RFS and accumulated plasma ctDNA status after RC. **E,** Kaplan–Meier survival analysis of OS and accumulated plasma ctDNA status after RC. **F,** Association between plasma ctDNA status after RC and recurrence. Recurrence was defined as detection of clinical recurrence from radiographic imaging results up to 2 years after the last plasma sample was analyzed. No recurrence was defined as absence of clinical recurrence during the surveillance period of up to 2 years after the last plasma sample was analyzed, including only patients with at least 2 years of follow-up after RC. **G,** One-year recurrence rates (left) and Kaplan–Meier survival analysis of RFS (right) for baseline ctDNA-negative patients in the NAC-treated and NAC-naïve cohorts. **H,** One-year recurrence rates (left) and Kaplan–Meier survival analysis of RFS (right) for baseline ctDNA-positive patients in the NAC-treated and NAC-naïve cohorts. HRs, associated 95% CIs, and P values are displayed on each Kaplan–Meier plot (Cox regression analysis). Significant statistical difference between ctDNA status and recurrence was determined using Fisher exact test.

bladder tumor (TURBT) alone was observed for 26% (27/102) and 16% (16/102) of the patients, respectively. Surgical downstaging was, however, not associated with improved RFS or OS (results not shown).

We hypothesized that patients without detectable ctDNA at diagnosis do not need NAC and would therefore have a similar recurrence rate as ctDNA-negative, NAC-treated patients. However, when comparing recurrence rates within 1 year after RC for patients who were ctDNA-negative at diagnosis between the two cohorts, we observed a recurrence rate of 10% (5/50) in NAC-naïve patients compared with 0% in NAC-treated patients. Notably, the difference in 1-year recurrence rates ($P = 0.07$) or RFS ($P = 0.05$) was not statistically significant (**Fig. 3G**). The RFS of ctDNA-positive patients in the NAC-naïve cohort was not shorter compared with ctDNA-positive patients in the NAC-treated cohort and we observed no difference in 1-year recurrence rates (**Fig. 3H**).

Due to the collection procedure of plasma samples in the NAC-naïve cohort, the volume of plasma obtained, the amount of extracted cfDNA, and the library input were significantly lower compared with the NAC-treated cohort, thus potentially reducing overall sensitivity of detecting ctDNA in the NAC-naïve cohort (Supplementary Fig. S3A–S3C). Five patients in the NAC-naïve cohort did not have detectable ctDNA at the pre-RC time point despite having metastatic relapse within 1 year after RC, but the quality of the samples from these patients was not found to be significantly lower compared with the remaining samples in the cohort (Supplementary Fig. S3D–S3F). The anatomical location of relapse, i.e., local versus distant relapse, was not significantly associated with either ctDNA status at diagnosis or after RC in any of the cohorts (results not shown). Despite the overall lower quality of samples in the NAC-naïve cohort, a strong prognostic value of ctDNA testing remained (**Fig. 3**).

Two patients in the NAC-treated cohort (4136 and 3923), who did not have metastatic relapse, were ctDNA-positive before RC (after NAC) and consistently ctDNA-negative during surveillance after RC (Supplementary Fig. S1). In the NAC-naïve cohort, four patients were ctDNA-positive before RC and ctDNA-negative after RC without having metastatic disease during the follow-up period (Supplementary Fig. S2). These might be cases where the ctDNA before RC solely originates from the primary tumor and/or regional lymph nodes rather than disseminated tumor cells, and RC is thereby curative due to completely localized disease.

Clinical and biological characterization of ctDNA shedding tumors

To study features of baseline ctDNA positivity, we combined all analyzed tumors and utilized the pre-NAC ctDNA status for NAC-treated patients and the pre-RC ctDNA status for NAC-naïve patients. In agreement with previous findings, ctDNA detection at baseline was associated with higher tumor stage ($P = 0.018$) and tumor size ($P = 0.016$) at TURBT (**Fig. 4A–B**). Smoking status of the patients was not associated with ctDNA positivity at baseline (**Fig. 4C**). Using the WES data from tumors, *TP53* was the only driver gene showing a higher mutation rate in ctDNA shedding tumors ($P = 0.007$; Supplementary Fig. S4A). We found no association between the number of somatic variants or contribution of mutational signatures and baseline ctDNA positivity (Supplementary Fig. S4B–D).

To explore ctDNA shedding biology further, total RNA-seq was performed on 162 tumors of which 131 passed quality control filtering. Tumors were classified according to the six MIBC consensus classes (18) and more Basal/Squamous (Ba/Sq) tumors were found among the ctDNA-positive patients ($P < 0.0001$; **Fig. 4D**), possibly reflecting the higher aggressiveness of Ba/Sq tumors compared with the luminal

subtypes. For ctDNA shedding tumors, ctDNA levels were not associated with tumor subtype classifications (Supplementary Fig. S4E). In both cohorts, gene set enrichment analysis using the Hallmark gene sets revealed an enrichment of oncogenic pathways, namely epithelial-to-mesenchymal transition (EMT; $q < 0.0001$), hypoxia ($q < 0.0001$), and cell cycle–associated gene sets (E2F targets, $q < 0.0001$ and G2M checkpoint, $q < 0.0001$) in tumors from ctDNA-positive patients ($n = 57/126$; **Fig. 4E**; Supplementary Fig. S4F). This may reflect a more aggressive cancer phenotype with metastatic abilities of ctDNA shedding tumors. Gene sets upregulated in patients who did not have ctDNA clearance after NAC ($n = 7$ patients) compared with patients with ctDNA clearance ($n = 11$ patients) included EMT ($q < 0.0001$), hypoxia ($q < 0.0001$), and TNFα signaling ($q < 0.0001$; **Fig. 4F**). When using clinical relapse within 1 year after RC as endpoint instead of ctDNA status, we found enrichment of the EMT and E2F targets in patients with metastatic relapse ($n = 32$ patients) whereas enrichment of antitumor immune pathways, including IFNα ($q < 0.0001$) and IFNγ response ($q < 0.0001$) was observed among patients without relapse ($n = 90$; **Fig. 4G**).

Discussion

Assessment of ctDNA is a promising minimally invasive blood-based biomarker in bladder cancer and here we underline its prognostic value in NAC-treated patients with >5 years of follow-up after RC. Accumulated ctDNA analysis after RC identified metastatic relapse with a sensitivity of 94% and specificity of 98%, highlighting the potential of ctDNA-guided prognostication and patient management using a personalized, tumor-informed assay. We observed a positive lead-time of ctDNA-based relapse detection of 123 days over radiographic imaging, and importantly we still observed a positive lead-time of 118 days when restricting the analysis to patients with simultaneous ctDNA analysis and radiographic imaging. The association between longer lead-times and a slower rise in ctDNA levels may reflect more indolent underlying tumor biology and supports the need for a frequent, quantitative assessment in this setting compared with a binary evaluation of ctDNA presence. Further studies and larger cohorts are needed to address the clinical potential of ctDNA growth rate assessment and determine the optimal time intervals for estimating growth rates.

We included analysis of a NAC-naïve patient cohort to evaluate the prognostic value of ctDNA in this setting. We found that the presence of ctDNA was highly associated with worse RFS as expected. When comparing outcomes across the patient cohorts, we observed a recurrence rate within 1 year after RC of 0% and 10% (nonsignificant) among baseline ctDNA-negative patients in the NAC-treated and NAC-naïve cohort, respectively. Of note, patients in the NAC-naïve cohort were selected to represent an equal number of patients with and without metastatic disease within the cohort, explaining the overall higher number of recurrence events observed in this cohort compared with the prospectively collected cohort of NAC-treated patients. Furthermore, the plasma sample quality and volume in the NAC-naïve cohort were lower compared with the samples in the NAC-treated cohort, potentially impacting sensitivity. We speculate that this might explain ctDNA negativity at baseline for the 5 patients experiencing metastatic relapse within 12 months after RC. Finally, the higher recurrence rate of the ctDNA-negative patients in the NAC-naïve cohort might also be caused by the presence of non-detected micrometastases or dormant carcinoma cells not eradicated by NAC. Larger studies in this setting may likely be able to demonstrate statistical significance. A randomized clinical trial is needed to

Figure 4.
Clinical and biological characterization of ctDNA shedding tumors. **A,** Association between baseline ctDNA status and tumor stage at TURBT including both patient cohorts. **B,** Association between baseline ctDNA status and tumor size at TURBT including both patient cohorts. **C,** Association between baseline ctDNA status and smoking status of patients including both cohorts. **D,** Association between baseline ctDNA status and MIBC consensus classification of tumors including both patient cohorts. Asterisks in color legend indicate subtypes that were significantly associated with shedding when compared with all other subtypes. **E,** Gene set enrichment analysis of tumors using the Hallmark pathways comparing baseline ctDNA shedding and non-shedding tumors from both cohorts. Only gene sets with a normalized enrichment score >2 are shown. **F,** Gene set enrichment analysis of tumors using the Hallmark pathways comparing patients with and without ctDNA clearance after NAC. **G,** Gene set enrichment analysis of tumors using the Hallmark pathways comparing patients with and without recurrence within 1 year after RC. Statistical significance of ctDNA status and other categorical variables was calculated using Fisher exact test. Gene sets in **E–G** are ordered by decreasing q-values and only gene sets with q values < 0.01 are shown.

establish whether baseline ctDNA-negative patients could potentially avoid NAC and its associated toxicity, or whether NAC is still indicated despite no ctDNA detection. No difference in RFS of ctDNA-positive patients was observed between patient cohorts; however, due to discrepancies between the cohorts, the interpretation of a cross-cohort comparison in both ctDNA-negative and positive patients has its limitations. There is potential to explore whether escalation of treatment will improve the outcome of the high-risk patients who are ctDNA-positive at diagnosis and do not respond to NAC (remain ctDNA-positive after NAC or become ctDNA-positive shortly after RC).

For the NAC-naïve patients, we observed a high rate of surgical downstaging at RC by TURBT alone. This further complicates the use of pathologic downstaging to evaluate response to NAC, as it is not possible to distinguish patients having pathologic downstaging due to NAC or due to the TURBT alone. Assessment of ctDNA as treatment response parameter has previously been explored in MIBC (5, 6). Here we found that ctDNA status and ctDNA dynamics during NAC were highly associated with pathologic downstaging. Furthermore, ctDNA status before RC and ctDNA dynamics during NAC both outperformed pathologic downstaging in predicting treatment efficacy and patient outcomes after RC. Defects in DNA damage repair (DDR)

genes have been shown to increase sensitivity to chemotherapy in bladder cancer (20–23) and several ongoing clinical trials are investigating bladder sparing for patients with alterations in DDR genes and complete pathologic response following NAC (24–26). The combined approach of ctDNA testing and assessment of DDR pathway alterations could potentially provide a refined selection of patients for bladder preserving protocols. However, other studies have observed no predictive power of DDR gene mutations (5, 27). A recent publication, where urinary tumor-derived DNA was evaluated for 56 of the 68 patients in the NAC-treated cohort (28), highlighted that a combined analysis of urine- and plasma samples in pre-RC setting may provide further strength to identify low-risk patients potentially eligible for bladder sparing approaches.

We sought to characterize the underlying biology of ctDNA shedding tumors and generally observed a more aggressive phenotype with enrichment of EMT and cell cycle–associated gene sets. These findings are in line with previous observations in lung cancer where ctDNA-positive adenocarcinomas also showed upregulation of proliferation and cell cycle–associated gene sets (13). In addition, we found more tumors of the Ba/Sq subtype among patients who were ctDNA-positive at baseline. This has previously been observed in MIBC (29) and a previous study on lung cancer found a higher ctDNA detection rate for squamous tumors compared with adenocarcinomas (11, 13), which was suggested to be caused by the more necrotic profile of squamous tumors. When using ctDNA dynamics to evaluate treatment response, we found enrichment of the hypoxia gene set amongst others in tumors from patients without ctDNA clearance during NAC. Hypoxia has been suggested to enhance chemoresistance and the metastatic potential of cancer cells (30), further linking ctDNA dynamics during treatment and lack of response to therapy. It should be noted that the clinical and molecular features associated with ctDNA shedding are *per se* associated with a more aggressive phenotype and hence, poorer patient outcome. Also, Ba/Sq tumors are known to be associated with EMT and a hypoxic environment (18, 31), meaning that ctDNA shedding may be an intrinsic biological feature of Ba/Sq tumors. Although causality is difficult to prove on the basis of this data, the results suggest that presence of EMT in the primary tumor might influence ctDNA shedding and that a high proliferation rate and overall necrotic profile increases the continuous shedding of ctDNA into circulation, making ctDNA detection in these patients more likely.

Implementation of ctDNA analysis in the management of patients with MIBC could potentially solve several clinical challenges, including early prognostication of patients, monitoring of treatment response, early detection of metastatic relapse and potentially selection of patients for bladder preserving protocols. Clinical trials evaluating ctDNA-guided adjuvant treatment with atezolizumab are currently ongoing (32, 33), but additional randomized trials evaluating ctDNA-stratified therapeutic and bladder preserving approaches are needed to further elucidate the full clinical potential of ctDNA assessment.

Authors' Contributions

S.V. Lindskrog: Conceptualization, data curation, formal analysis, funding acquisition, validation, investigation, visualization, methodology, writing–original draft, writing–review and editing. **K. Birkenkamp-Demtröder:** Conceptualization, data curation, writing–review and editing. **I. Nordentoft:** Conceptualization, data curation, writing–review and editing. **G. Laliotis:** Formal analysis, investigation, writing–review and editing. **P. Lamy:** Formal analysis, methodology, writing–review and editing. **E. Christensen:** Conceptualization, formal analysis, investigation, writing–review and editing. **D. Renner:** Writing–review and editing. **T.G. Andreasen:** Data curation, writing–review and editing. **N. Lange:** Formal analysis, investigation, writing–review and editing. **S. Sharma:** Conceptualization, writing–review and editing. **A.C. ElNaggar:** Writing–review and editing. **M.C. Liu:** Writing–review and editing. **H. Sethi:** Conceptualization, writing–review and editing. **A. Aleshin:** Conceptualization, writing–review and editing. **M. Agerbæk:** Data curation, writing–review and editing. **J.B. Jensen:** Resources, data curation, writing–review and editing. **L. Dyrskjøt:** Conceptualization, resources, supervision, funding acquisition, investigation, writing–original draft, project administration, writing–review and editing.

Note

Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49.
2. Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 2021;79:82–104.
3. Niedersüss-Beke D, Puntus T, Kunit T, Grünberger B, Lamche M, Loidl W, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin in patients with locally advanced bladder cancer. Oncology 2017;93:36–42.
4. Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2015;67:241–9.
5. Christensen E, Birkenkamp-Demtröder K, Sethi H, Shchegrova S, Salari R, Nordentoft I, et al. Early detection of metastatic relapse and monitoring of

therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol 2019;37:1547–57.

6. Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 2021; 595:432–7.

7. van Dorp J, Pipinikas C, Suelmann BBM, Mehra N, van Dijk N, Marsico G, et al. High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. Nat Med 2023;29:588–92.

8. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.

9. Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 2017;545:446–51.

10. Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol 2018; 15:577–86.

11. Sánchez-Herrero E, Serna-Blasco R, Robado de Lope L, González-Rumayor V, Romero A, Provencio M. Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis. Front Oncol 2022;12:943253.

12. Hsiehchen D, Espinoza M, Gerber DE, Beg MS. Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay. Cancer Biol Ther 2021; 22:455–64.

13. Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature 2023;616:553–62.

14. Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, et al. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature 2022;608:199–208.

15. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.

16. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019;95:103208.

17. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods 2017;14:417–9.

18. Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 2020;77:420–33.

19. Körner SK, Jensen JB. A population-based retrospective analysis on variation in use of neoadjuvant chemotherapy depending on comorbidity in patients with muscle-invasive bladder cancer undergoing cystectomy in Denmark in the period 2013–2019. Scand J Urol 2022;56:34–8.

20. Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014;4:1140–53.

21. Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol 2015;68:959–67.

22. Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, et al. DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. Clin Cancer Res 2017;23:3610–8.

23. Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM, et al. Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer. J Clin Oncol 2018; 36:1949–56.

24. ClinicalTrials.gov. Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) . 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT02710734.

25. ClinicalTrials.gov. Gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing. 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT03558087.

26. ClinicalTrials.gov. Gemcitabine and cisplatin without cystectomy for patients with muscle-invasive bladder urothelial cancer and select genetic alterations. 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT03609216.

27. Taber A, Christensen E, Lamy P, Nordentoft I, Prip F, Lindskrog SV, et al. Molecular correlates of cisplatin-based chemotherapy response in muscle-invasive bladder cancer by integrated multi-omics analysis. Nat Commun 2020;11:4858.

28. Christensen E, Nordentoft I, Birkenkamp-Demtröder K, Elbæk SK, Lindskrog SV, Taber A, et al. Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer. Clin Cancer Res 2023;29:1582–91.

29. Szabados B, Kockx M, Assaf ZJ, van Dam P-J, Rodriguez-Vida A, Duran I, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol 2022;82:212–22.

30. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11:393–410.

31. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 2017;171:540–56.

32. ClinicalTrials.gov. A study of atezolizumab versus placebo as adjuvant therapy in patients with high-risk muscle-invasive bladder cancer who are ctDNA-positive following cystectomy (IMvigor011). 2023. Available from: https://clinicaltrials.gov/ct2/show/NCT04660344.

33. ClinicalTrials.gov. Treatment of metastatic bladder cancer at the time of biochemical reLApse following radical cystectomy (TOMBOLA). 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT04138628.